Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer

 
• By Emily Hayes

Success of Keytruda/chemo combo in KEYNOTE-189 first-line metastatic lung cancer study restores Merck's leadership in immuno-oncology and may drive more use, though doctors are still looking to see more data, especially for PD-L1 subgroups.

Dart arrow hitting in the target center of dartboard using as background Target business, achieve and victory,success concept.

More from Clinical Trials

More from R&D